查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1405866

糖尿病視網膜病變市場規模、佔有率、趨勢分析報告：按類型、管理、地區、細分市場預測，2024-2030 年

Diabetic Retinopathy Market Size, Share & Trends Analysis Report By Type (Proliferative DR, Non-Proliferative DR), By Management (Anti-VEGF Therapy, Intraocular Steroid Injection, Laser Surgery, Vitrectomy), By Region, & Segment Forecasts, 2024-2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

糖尿病視網膜病變市場成長與趨勢：

Grand View Research, Inc.最新報告預測，到2030年，全球糖尿病視網膜病變市場規模預計將達到137.7億美元，2024年至2030年複合年成長率為6.43%。

糖尿病盛行率上升、老年人口增加以及糖尿病導致失明率上升是預計在預測期內推動市場成長的主要因素。有關糖尿病管理和護理的意識不斷提高和新產品的推出進一步推動了市場成長。糖尿病視網膜病變是由視網膜血管損傷引起的，通常會導致Sumiya Co., Ltd.和視力下降。

由於高齡化、肥胖和不健康的生活方式，糖尿病盛行率不斷上升，推動了市場的成長。肥胖是引發糖尿病的主要因素。據世界衛生組織稱，到 2021 年，全球 18 歲以上成年人中約有 39% 超重，13% 肥胖。除了肥胖之外，糖尿病在世界各地也變得越來越普遍。根據國際糖尿病聯盟（IDF）估計，2021年將有5.37億成年人（20歲至79歲）患有糖尿病，預計2040年將增加至6.42億。 IDF 還報告稱，全球糖尿病盛行率正在上升，其中低收入和中等收入國家的增幅最高。 2021年糖尿病患者人數最多的地區是亞太地區（1.67億人）、南亞（8,800萬人）和歐洲（5,900萬人）。

老年人口的增加是糖尿病流行的重要促進因素，因為老年人的糖尿病與死亡率增加和功能狀態下降有直接關係。據世界衛生組織稱，到2050年，預計80%的老年人將生活在低收入和中等收入國家。人口高齡化速度比過去高很多。 2020年，60歲以上老年人口數量超過5歲以下兒童數。 2015年至2050年間，全球60歲以上人口比例將增加近一倍，從12%增加至22%。

糖尿病視網膜病變市場報告亮點

  • 就2023年按類型分類的佔有率而言，非增殖性糖尿病視網膜病變將佔最大佔有率。大量糖尿病史不到10年的患者增加了該細分市場的市場規模。
  • 2023年，依管理層分類，抗VEGF藥物領域佔最大佔有率。這些藥物在治療輕中度非增殖性 DR 的早期診斷和高適用性是指導此細分市場成長的主要因素之一。
  • 預計亞太市場在預測期內將以最高複合年成長率成長。該地區人口眾多、糖尿病盛行率高以及老年人口不斷增加可能會增強該市場。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第 3 章 糖尿病視網膜病變市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場抑制因素分析
  • 糖尿病視網膜病變市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章 糖尿病視網膜病變市場：類型估計與趨勢分析

  • 類型市場佔有率，2023/2030
  • 細分儀表板
  • 按類型分類的全球糖尿病視網膜病變市場展望
  • 2018-2030 年市場規模、預測與趨勢分析如下
    • 增殖性糖尿病視網膜病變
    • 非增殖性糖尿病視網膜病變

第5章糖尿病視網膜病變市場：管理階層估計與趨勢分析

  • 管理市場佔有率，2023/2030
  • 細分儀表板
  • 按管理前景分類的全球糖尿病視網膜病變市場
  • 2018-2030 年市場規模、預測與趨勢分析如下
    • 抗VEGF
    • 類固醇眼內注射
    • 雷射手術
    • 玻璃體切除術

第6章 糖尿病視網膜病變市場：區域估計與趨勢分析

  • 2023/2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 全球區域市場概況
  • 2018-2030 年市場規模與預測/趨勢分析：
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章競爭形勢

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭分類
  • 供應商形勢
    • List of key distributors and channel partners
    • Key customers
    • Key company market share analysis, 2023
    • Bayer AG
    • ABBVIE INC.
    • Novartis AG
    • Oxurion NV
    • Sirnaomics
    • Alimera Sciences
    • Ampio Pharmaceuticals Inc.
    • BCNPeptides
    • Kowa Company Ltd.
    • Genentech, Inc.
Product Code: 978-1-68038-466-6

Diabetic Retinopathy Market Growth & Trends:

The global diabetic retinopathy market size is anticipated to reach USD 13.77 billion by 2030 and is anticipated to expand at a CAGR of 6.43% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising prevalence of diabetes, growing geriatric population, and increasing prevalence of blindness due to diabetes are the major factors anticipated to boost market growth over the forecast period. Growth in the market is further propelled by the increasing awareness about diabetes management & care and new product launches. Diabetic retinopathy is caused by damage to the blood vessels in the retina, which leads to blurred vision and vision loss in most cases.

The increase in prevalence of diabetes due to aging, obesity, and unhealthy lifestyles is contributing to the growth of the market. Obesity is a major factor leading to diabetes. According to WHO, in 2021, around 39% of adults aged 18 years and above were overweight, and 13% were obese worldwide. In addition to obesity, diabetes is becoming increasingly prevalent globally. The International Diabetes Federation (IDF) estimated l537 million adults (aged 20 to 79 years) were living with diabetes in 2021, which is expected to rise to 642 million by 2040. The IDF also reports that the prevalence of diabetes is increasing globally, with the highest increases witnessed in low- and middle-income countries. In 2021, the regions with the highest number of adults living with diabetes were the Western Pacific (167 million), South Asia (88 million), and Europe (59 million).

The rising geriatric population is a significant driver of the diabetes epidemic, as diabetes in older people is directly linked with higher mortality and reduced functional status. According to WHO, 80% of older people are expected to live in low- and middle-income nations by 2050. The population is aging at a considerably higher rate than in the past. In 2020, the number of persons aged 60 years and more will outnumber children under the age of 5 years. Between 2015 and 2050, the proportion of the global population aged over 60 years will nearly double, from 12% to 22%.

Diabetic Retinopathy Market Report Highlights:

  • Non-proliferative diabetic retinopathy accounted for the largest share, by type, in 2023. The presence of large number of patients within the bracket of less than 10 years of diabetic history contributed to the large size of this segment.
  • Anti-VEGF segment accounted for the largest share, by management, in 2023. High applicability of these drugs in treatment of early diagnosis and mild to moderate cases of non-proliferative DR treatment is among the prime factors leading to segmental growth.
  • The Asia Pacific market is expected to grow with the highest CAGR over the forecast period. Large population base in this region, high prevalence of diabetes, and rising geriatric population are likely to bolster the market.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Management
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type outlook
    • 2.2.2. Management outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Diabetic Retinopathy Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of diabetes
      • 3.2.1.2. Growing geriatric population
      • 3.2.1.3. Increasing prevalence of blindness due to diabetes
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Lack of accurate diagnosis
      • 3.2.2.2. Adverse effect on treatment
  • 3.3. Diabetic Retinopathy Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape

Chapter 4. Diabetic Retinopathy Market: Type Estimates & Trend Analysis

  • 4.1. Type Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Diabetic Retinopathy Market by Type Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Proliferative Diabetic Retinopathy
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Non-proliferative Diabetic Retinopathy
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Diabetic Retinopathy Market: Management Estimates & Trend Analysis

  • 5.1. Management Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Diabetic Retinopathy Market by Management Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Anti-VEGF
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Intraocular Steroid Injection
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Laser Surgery
      • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.4. Vitrectomy
      • 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Diabetic Retinopathy Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2023 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Global Regional Market Snapshot
  • 6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.5. North America
    • 6.5.1. U.S.
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.2. Canada
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Europe
    • 6.6.1. UK
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.2. Germany
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.3. France
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework/ reimbursement structure
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.4. Italy
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Regulatory framework/ reimbursement structure
      • 6.6.4.3. Competitive scenario
      • 6.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.5. Spain
      • 6.6.5.1. Key country dynamics
      • 6.6.5.2. Regulatory framework/ reimbursement structure
      • 6.6.5.3. Competitive scenario
      • 6.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.6. Norway
      • 6.6.6.1. Key country dynamics
      • 6.6.6.2. Regulatory framework/ reimbursement structure
      • 6.6.6.3. Competitive scenario
      • 6.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.7. Sweden
      • 6.6.7.1. Key country dynamics
      • 6.6.7.2. Regulatory framework/ reimbursement structure
      • 6.6.7.3. Competitive scenario
      • 6.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.8. Denmark
      • 6.6.8.1. Key country dynamics
      • 6.6.8.2. Regulatory framework/ reimbursement structure
      • 6.6.8.3. Competitive scenario
      • 6.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. Asia Pacific
    • 6.7.1. Japan
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.2. China
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.3. India
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.4. Australia
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.5. South Korea
      • 6.7.5.1. Key country dynamics
      • 6.7.5.2. Regulatory framework/ reimbursement structure
      • 6.7.5.3. Competitive scenario
      • 6.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.6. Thailand
      • 6.7.6.1. Key country dynamics
      • 6.7.6.2. Regulatory framework/ reimbursement structure
      • 6.7.6.3. Competitive scenario
      • 6.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8. Latin America
    • 6.8.1. Brazil
      • 6.8.1.1. Key country dynamics
      • 6.8.1.2. Regulatory framework/ reimbursement structure
      • 6.8.1.3. Competitive scenario
      • 6.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.8.2. Mexico
      • 6.8.2.1. Key country dynamics
      • 6.8.2.2. Regulatory framework/ reimbursement structure
      • 6.8.2.3. Competitive scenario
      • 6.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.8.3. Argentina
      • 6.8.3.1. Key country dynamics
      • 6.8.3.2. Regulatory framework/ reimbursement structure
      • 6.8.3.3. Competitive scenario
      • 6.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9. MEA
    • 6.9.1. South Africa
      • 6.9.1.1. Key country dynamics
      • 6.9.1.2. Regulatory framework/ reimbursement structure
      • 6.9.1.3. Competitive scenario
      • 6.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.2. Saudi Arabia
      • 6.9.2.1. Key country dynamics
      • 6.9.2.2. Regulatory framework/ reimbursement structure
      • 6.9.2.3. Competitive scenario
      • 6.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.3. UAE
      • 6.9.3.1. Key country dynamics
      • 6.9.3.2. Regulatory framework/ reimbursement structure
      • 6.9.3.3. Competitive scenario
      • 6.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.4. Kuwait
      • 6.9.4.1. Key country dynamics
      • 6.9.4.2. Regulatory framework/ reimbursement structure
      • 6.9.4.3. Competitive scenario
      • 6.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company market share analysis, 2023
    • 7.3.4. Bayer AG
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Product benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. ABBVIE INC.
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Product benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. Novartis AG
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Product benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. Oxurion NV
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Product benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. Sirnaomics
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Product benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Alimera Sciences
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Product benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. Ampio Pharmaceuticals Inc.
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Product benchmarking
      • 7.3.10.4. Strategic initiatives
    • 7.3.11. BCNPeptides
      • 7.3.11.1. Company overview
      • 7.3.11.2. Financial performance
      • 7.3.11.3. Product benchmarking
      • 7.3.11.4. Strategic initiatives
    • 7.3.12. Kowa Company Ltd.
      • 7.3.12.1. Company overview
      • 7.3.12.2. Financial performance
      • 7.3.12.3. Product benchmarking
      • 7.3.12.4. Strategic initiatives
    • 7.3.13. Genentech, Inc.
      • 7.3.13.1. Company overview
      • 7.3.13.2. Financial performance
      • 7.3.13.3. Product benchmarking
      • 7.3.13.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America refurbished MRI systems market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America refurbished MRI systems market, by technology, 2018 - 2030 (USD Million)
  • Table 4 North America refurbished MRI systems market, by management, 2018 - 2030 (USD Million)
  • Table 5 U.S. refurbished MRI systems market, by technology, 2018 - 2030 (USD Million)
  • Table 6 U.S. refurbished MRI systems market, by management, 2018 - 2030 (USD Million)
  • Table 7 Canada refurbished MRI systems market, by technology, 2018 - 2030 (USD Million)
  • Table 8 Canada refurbished MRI systems market, by management, 2018 - 2030 (USD Million)
  • Table 9 Europe refurbished MRI systems market, by region, 2018 - 2030 (USD Million)
  • Table 10 Europe refurbished MRI systems market, by technology, 2018 - 2030 (USD Million)
  • Table 11 Europe refurbished MRI systems market, by management, 2018 - 2030 (USD Million)
  • Table 12 Germany refurbished MRI systems market, by technology, 2018 - 2030 (USD Million)
  • Table 13 Germany refurbished MRI systems market, by management, 2018 - 2030 (USD Million)
  • Table 14 UK refurbished MRI systems market, by technology, 2018 - 2030 (USD Million)
  • Table 15 UK refurbished MRI systems market, by management, 2018 - 2030 (USD Million)
  • Table 16 France refurbished MRI systems market, by technology, 2018 - 2030 (USD Million)
  • Table 17 France refurbished MRI systems market, by management, 2018 - 2030 (USD Million)
  • Table 18 Italy refurbished MRI systems market, by technology, 2018 - 2030 (USD Million)
  • Table 19 Italy refurbished MRI systems market, by management, 2018 - 2030 (USD Million)
  • Table 20 Spain refurbished MRI systems market, by technology, 2018 - 2030 (USD Million)
  • Table 21 Spain refurbished MRI systems market, by management, 2018 - 2030 (USD Million)
  • Table 22 Denmark refurbished MRI systems market, by technology, 2018 - 2030 (USD Million)
  • Table 23 Denmark refurbished MRI systems market, by management, 2018 - 2030 (USD Million)
  • Table 24 Sweden refurbished MRI systems market, by technology, 2018 - 2030 (USD Million)
  • Table 25 Sweden refurbished MRI systems market, by management, 2018 - 2030 (USD Million)
  • Table 26 Norway refurbished MRI systems market, by technology, 2018 - 2030 (USD Million)
  • Table 27 Norway refurbished MRI systems market, by management, 2018 - 2030 (USD Million)
  • Table 28 Asia Pacific refurbished MRI systems market, by region, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific refurbished MRI systems market, by technology, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific refurbished MRI systems market, by management, 2018 - 2030 (USD Million)
  • Table 31 China refurbished MRI systems market, by technology, 2018 - 2030 (USD Million)
  • Table 32 China refurbished MRI systems market, by management, 2018 - 2030 (USD Million)
  • Table 33 Japan refurbished MRI systems market, by technology, 2018 - 2030 (USD Million)
  • Table 34 Japan refurbished MRI systems market, by management, 2018 - 2030 (USD Million)
  • Table 35 India refurbished MRI systems market, by technology, 2018 - 2030 (USD Million)
  • Table 36 India refurbished MRI systems market, by management, 2018 - 2030 (USD Million)
  • Table 37 South Korea refurbished MRI systems market, by technology, 2018 - 2030 (USD Million)
  • Table 38 South Korea refurbished MRI systems market, by management, 2018 - 2030 (USD Million)
  • Table 39 Australia refurbished MRI systems market, by technology, 2018 - 2030 (USD Million)
  • Table 40 Australia refurbished MRI systems market, by management, 2018 - 2030 (USD Million)
  • Table 41 Thailand refurbished MRI systems market, by technology, 2018 - 2030 (USD Million)
  • Table 42 Thailand refurbished MRI systems market, by management, 2018 - 2030 (USD Million)
  • Table 43 Latin America refurbished MRI systems market, by technology, 2018 - 2030 (USD Million)
  • Table 44 Latin America refurbished MRI systems market, by management, 2018 - 2030 (USD Million)
  • Table 45 Brazil refurbished MRI systems market, by technology, 2018 - 2030 (USD Million)
  • Table 46 Brazil refurbished MRI systems market, by management, 2018 - 2030 (USD Million)
  • Table 47 Mexico refurbished MRI systems market, by technology, 2018 - 2030 (USD Million)
  • Table 48 Mexico refurbished MRI systems market, by management, 2018 - 2030 (USD Million)
  • Table 49 Argentina refurbished MRI systems market, by technology, 2018 - 2030 (USD Million)
  • Table 50 Argentina refurbished MRI systems market, by management, 2018 - 2030 (USD Million)
  • Table 51 MEA refurbished MRI systems market, by region, 2018 - 2030 (USD Million)
  • Table 52 MEA refurbished MRI systems market, by technology, 2018 - 2030 (USD Million)
  • Table 53 MEA refurbished MRI systems market, by management, 2018 - 2030 (USD Million)
  • Table 54 South Africa refurbished MRI systems market, by technology, 2018 - 2030 (USD Million)
  • Table 55 South Africa refurbished MRI systems market, by management, 2018 - 2030 (USD Million)
  • Table 56 Saudi Arabia refurbished MRI systems market, by technology, 2018 - 2030 (USD Million)
  • Table 57 Saudi Arabia refurbished MRI systems market, by management, 2018 - 2030 (USD Million)
  • Table 58 UAE refurbished MRI systems market, by technology, 2018 - 2030 (USD Million)
  • Table 59 UAE refurbished MRI systems market, by management, 2018 - 2030 (USD Million)
  • Table 60 Kuwait refurbished MRI systems market, by technology, 2018 - 2030 (USD Million)
  • Table 61 Kuwait refurbished MRI systems market, by management, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Refurbished MRI systems market: market outlook
  • Fig. 14 Refurbished MRI systems competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Refurbished MRI systems market driver impact
  • Fig. 20 Refurbished MRI systems market restraint impact
  • Fig. 21 Refurbished MRI systems market strategic initiatives analysis
  • Fig. 22 Refurbished MRI systems market: Type movement analysis
  • Fig. 23 Refurbished MRI systems market: Type outlook and key takeaways
  • Fig. 24 Proliferative diabetic retinopathy market estimates and forecast, 2018 - 2030
  • Fig. 25 Non-proliferative diabetic retinopathy estimates and forecast, 2018 - 2030
  • Fig. 26 Refurbished MRI systems Market: Management movement Analysis
  • Fig. 27 Refurbished MRI systems market: Management outlook and key takeaways
  • Fig. 28 Anti-VEGF market estimates and forecasts, 2018 - 2030
  • Fig. 29 Laser surgery market estimates and forecasts,2018 - 2030
  • Fig. 30 Vitrectomy market estimates and forecasts,2018 - 2030
  • Fig. 31 Global refurbished MRI systems market: Regional movement analysis
  • Fig. 32 Global refurbished MRI systems market: Regional outlook and key takeaways
  • Fig. 33 Global refurbished MRI systems market share and leading players
  • Fig. 34 North America market share and leading players
  • Fig. 35 Europe market share and leading players
  • Fig. 36 Asia Pacific market share and leading players
  • Fig. 37 Latin America market share and leading players
  • Fig. 38 Middle East & Africa market share and leading players
  • Fig. 39 North America: SWOT
  • Fig. 40 Europe SWOT
  • Fig. 41 Asia Pacific SWOT
  • Fig. 42 Latin America SWOT
  • Fig. 43 MEA SWOT
  • Fig. 44 North America, by country
  • Fig. 45 North America
  • Fig. 46 North America market estimates and forecasts, 2018 - 2030
  • Fig. 47 U.S.
  • Fig. 48 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 49 Canada
  • Fig. 50 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 51 Europe
  • Fig. 52 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 53 UK
  • Fig. 54 UK market estimates and forecasts, 2018 - 2030
  • Fig. 55 Germany
  • Fig. 56 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 57 France
  • Fig. 58 France market estimates and forecasts, 2018 - 2030
  • Fig. 59 Italy
  • Fig. 60 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 61 Spain
  • Fig. 62 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 63 Denmark
  • Fig. 64 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 65 Sweden
  • Fig. 66 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 67 Norway
  • Fig. 68 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 69 Asia Pacific
  • Fig. 70 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 71 China
  • Fig. 72 China market estimates and forecasts, 2018 - 2030
  • Fig. 73 Japan
  • Fig. 74 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 75 India
  • Fig. 76 India market estimates and forecasts, 2018 - 2030
  • Fig. 77 Thailand
  • Fig. 78 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 79 South Korea
  • Fig. 80 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 81 Australia
  • Fig. 82 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 83 Latin America
  • Fig. 84 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 85 Brazil
  • Fig. 86 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 87 Mexico
  • Fig. 88 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 89 Argentina
  • Fig. 90 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 91 Middle East and Africa
  • Fig. 92 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 93 South Africa
  • Fig. 94 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 95 Saudi Arabia
  • Fig. 96 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 97 UAE
  • Fig. 98 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 99 Kuwait
  • Fig. 100 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 101 Market share of key market players - Diabetic retinopathy market